Teva Pharmaceutical Industries (TEVA) On Celiac Trial Results And New Notes Looks Undervalued
Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after reporting positive Phase 2a topline results for its anti IL 15 antibody in celiac disease, alongside plans to issue new senior notes.
Teva Pharmaceutical Industries has seen solid momentum build, with the share price return of 9.47% over 90 days and 18.77% year to date, while the 1 year total shareholder return of 86.79% and 5 year total shareholder return of about 3x point to a much stronger long term recovery backdrop.
Scan beyond Teva Pharmaceutical Industries and size up other potential recovery stories with our hand picked 49 high quality undervalued stocks that also pair balance sheet strength with meaningful cash flow.
Teva Pharmaceutical Industries now trades at $36.76, with a roughly 13% gap to the average analyst target and a much wider implied discount to some fair value models. Is that spread still offering enough compensation for the risk?
Most Popular Narrative: 10.1% Undervalued
Against Teva Pharmaceutical Industries' last close at $36.76, the most followed valuation storyline pins fair value closer to $40.90, using an 8.58% discount rate to weigh future cash flows.
Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.
Want to see what kind of revenue runway and margin shift that product mix story actually assumes? The narrative leans on earnings power, mix upgrade, and a richer multiple that many investors normally associate with faster growing sectors rather than a large generic drug maker.
Result: Fair Value of $40.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Teva Pharmaceutical Industries faces pressure points, including reliance on a small group of branded drugs and a heavy debt load that could limit its flexibility in the future.
Find out about the key risks to this Teva Pharmaceutical Industries narrative.
Another View on Teva Pharmaceutical Industries Valuation
The fair value story for Teva Pharmaceutical Industries looks very different when switching from cash flow modeling to simple earnings multiples. The stock trades on a P/E of 60.7x, well above the US Pharmaceuticals group at 16.2x and the peer average of 18.9x, and also ahead of a 33.7x fair ratio.
This kind of premium leaves less room for disappointment if forecasts or sentiment cool from here. The question is whether you think Teva Pharmaceutical Industries has already priced in much of the recovery, or if the market could still push the P/E closer to that fair ratio over time.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mix of optimism and concern around Teva Pharmaceutical Industries is clear, so now is the time to review the data yourself and decide where you stand. To see both sides of the argument in one place, start with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Teva Pharmaceutical Industries?
If Teva Pharmaceutical Industries has you rethinking what a recovery story can look like, do not stop at one ticker. Broaden your watchlist and stack the odds in your favor.
- Target resilient balance sheets and durable cash flows by reviewing our list of solid balance sheet and fundamentals (24 results), which filters for stronger financial footing.
- Hunt for potential mispricings by scanning the 49 high quality undervalued stocks, which blends quality fundamentals with valuations that may still leave room for upside.
- Prioritize consistency and income stability by checking the 6 dividend fortresses, which highlights higher yielding companies with more robust payout profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com